Urolithin A and Mitopure: What 2024-2025 Clinical Trials Actually Show About Muscle and Mitochondria

The Pomegranate Paradox Nobody Talks About

Here's something that might ruin your expensive cold-pressed pomegranate juice habit: in a study of 100 healthy adults, only about 40% turned a glass of pomegranate juice into meaningful amounts of urolithin A. The rest produced little or none, because their gut bacteria couldn't efficiently convert the ellagitannins into the active compound that's been making headlines for mitochondrial health.

I went through the published human trials on urolithin A, from the first-in-human study in 2019 to trials reported through 2025. What I found was a messy but fascinating picture—one where the science is genuinely promising, but the marketing has sprinted miles ahead of the evidence.

What Urolithin A Actually Does (The Mitophagy Story)

Your cells have a quality control system for mitochondria. When these cellular power plants get damaged or worn out, a process called mitophagy tags them for recycling. Think of it like your body's internal Marie Kondo, clearing out mitochondria that no longer spark ATP.

Urolithin A activates this cleanup crew—at least in lab and animal studies, where it induced mitophagy, extended lifespan in worms (C. elegans), and improved exercise capacity in rodents. In humans, the first clinical trial (Nature Metabolism, 2019) found that 4 weeks of 500 mg or 1,000 mg daily had a favorable safety profile and shifted plasma acylcarnitines and muscle mitochondrial gene expression in sedentary older adults.

That's a molecular signal, not yet a clinical outcome. Whether it translates into stronger, more resilient muscles is what the later trials tried to answer.

Following the Money: Amazentis-Funded vs Independent Research

Amazentis makes Mitopure, the most studied urolithin A supplement. They've funded the majority of published trials, which immediately raises eyebrows. Should it?

Let's look at the details. The two best-known muscle trials—in older adults (JAMA Network Open, 2022) and middle-aged adults (Cell Reports Medicine, 2022)—were sponsored by Amazentis or included company employees among the authors. Truly independent replication is still limited.

The JAMA Network Open trial, run in Seattle, randomized 66 adults aged 65 to 90 to 1,000 mg of urolithin A or placebo for 4 months. Its primary endpoints—6-minute walk distance and maximal ATP production in a hand muscle—did not improve significantly versus placebo. Muscle endurance (contractions until fatigue in hand and leg muscles) did improve at 2 months, and blood levels of several acylcarnitines, ceramides, and C-reactive protein fell.

The Cell Reports Medicine trial gave 88 adults aged 40 to 64 either 500 mg or 1,000 mg daily for 4 months. It reported roughly 12% gains in muscle strength and favorable changes in aerobic endurance and walking performance, but its primary endpoint—peak power output—did not significantly improve.

I'm not suggesting fraud. These were randomized, placebo-controlled trials. But when the primary endpoints miss and the positive findings come from secondary measures, the honest summary is "modest and still being confirmed," not "proven."

The Gut Microbiome Problem (And Why You're Probably a Non-Responder)

Turning ellagitannins into urolithin A depends on specific gut bacteria (species such as Gordonibacter and Ellagibacter have been identified as producers). In a 100-person study published in the European Journal of Clinical Nutrition (2022), only 12% of participants had detectable urolithin A at baseline, and about 40% converted a glass of pomegranate juice into significant amounts.

The remaining majority? They could keep drinking pomegranate juice and still produce little urolithin A.

Age matters too. In a Spanish cohort of 839 people aged 5 to 90 (Food & Function, 2018), age was the main factor shaping a person's urolithin "metabotype"—that is, whether and how their gut bacteria convert ellagitannins.

This explains why direct urolithin A supplementation exists. You're bypassing the gut bacteria lottery entirely. Whether that's worth the cost depends on your individual situation—but at least the biological rationale is sound.

Mitopure vs Pomegranate Extract: The Head-to-Head Data

The most direct comparison comes from that same 2022 study, which was sponsored by Amazentis. Healthy adults were randomized to either a glass of pomegranate juice or a food product containing 500 mg of urolithin A.

Direct supplementation raised blood urolithin A levels consistently and delivered more than 6-fold greater exposure than pomegranate juice, whose results depended heavily on whether a person was a producer.

Note what this study did and didn't measure: blood levels, not muscle or health outcomes. Higher exposure is a plausible prerequisite for benefit—not proof of it.

Who Actually Benefits? Parsing the Subgroup Analyses

Not everyone needs urolithin A supplementation, and the trials don't yet define a clear "responder" profile.

Most human data come from sedentary middle-aged and older adults, which is where the muscle endurance and strength signals were seen. The idea that people with weaker baseline mitochondrial function benefit more is plausible, but it hasn't been established in trials.

In athletes, the results are mixed. In 42 highly trained male distance runners (Sports Medicine, 2025), 1,000 mg daily for 4 weeks did not improve 3,000 m time-trial performance, although perceived exertion and a marker of muscle damage were lower. A small 8-week trial in 20 resistance-trained men (Journal of the International Society of Sports Nutrition, 2024) reported better isometric strength and repetitions to failure than placebo, but no significant difference in one-rep max.

The Biomarker Validation Problem

How do we know urolithin A actually improves mitochondrial function in humans, not just cell cultures?

The middle-aged trial in Cell Reports Medicine went beyond blood tests: muscle biopsies showed higher levels of proteins linked to mitophagy and mitochondrial metabolism after supplementation. The 2019 first-in-human study also found changes in muscle mitochondrial gene expression.

Those are meaningful mechanistic signals. But they're still intermediate markers—not proof of better day-to-day function, fewer falls, or a longer healthspan.

Muscle biopsies are invasive and expensive, so most trials lean on blood biomarkers such as acylcarnitines and C-reactive protein, which relate to mitochondrial efficiency and inflammation but don't measure mitochondrial function directly. Useful but imperfect.

What the Longevity Community Gets Wrong

Scroll through any longevity forum and you'll find urolithin A discussed alongside rapamycin and metformin as a proven anti-aging intervention. That's premature.

We have early evidence for changes in mitochondrial biomarkers and modest muscle effects over 1 to 4 months. We have zero long-term human data on lifespan or healthspan outcomes. The lifespan extension in the original 2016 study was seen in worms (C. elegans); in rodents, the reported benefit was exercise capacity, not lifespan.

The mechanism is plausible. Mitochondrial dysfunction drives aging. Urolithin A improves mitochondrial function. Therefore urolithin A slows aging. That syllogism might be correct, but we're years away from proving it.

I'd put urolithin A in the "promising but unproven for longevity" category—alongside NAD+ precursors and spermidine. The mitochondrial and muscle data justify interest. The anti-aging claims require patience.

Making a Decision With Incomplete Information

If you're older, relatively sedentary, and noticing muscle weakness or fatigue, urolithin A is a reasonable topic to raise with your doctor—but expect modest effects at best. In the older-adult trial, the main endpoints didn't improve; the gains showed up in secondary muscle endurance measures.

If you're younger and active, your money probably goes further toward better sleep, consistent exercise, and adequate protein intake. The trials simply don't show meaningful benefits in healthy younger adults.

If you're committed to pomegranate-based approaches, know that there's no simple way to check whether you're a producer: urolithin metabotype testing is still mainly a research tool. Without the right bacteria, you're largely paying for fruit sugar.

The science here is genuinely interesting. The mitophagy mechanism is well-established. The human trials show real effects in the right populations. Just don't let the marketing convince you that we've cracked the aging code. We're still in the early chapters.